References
- Constantinou M, Jhanji V, Chiang PP, et al. Determinants of informed consent in a cataract surgery clinical trial: why patients participate. Can J Ophthalmol. 2012;47:118–123.
- Shah A, Efstathiou JA, Paly JJ, et al. Prospective preference assessment of patients’ willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:e13–e19.
- Scheck McAlearney A, Song PH, Reiter KL. Why providers participate in clinical trials: considering the National Cancer Institute’s Community Clinical Oncology Program. Contemp Clin Trials. 2012;33:1143–1149.
- Kasner SE, Del Giudice A, Rosenberg S, et al. Who will participate in acute stroke trials? Neurology. 2009;72:1682–1688.
- Jenkins V, Farewell D, Batt L, et al. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. Br J Cancer. 2010;103:1801–1807.
- Verheggen FW, Nieman F, Jonkers R. Determinants of patient participation in clinical studies requiring informed consent: why patients enter a clinical trial. Patient Educ Couns. 1998;35:111–125.
- Tamblyn R, Eguale T, Huang A, et al. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med. 2014;160:441–450.
- Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.
- http://www.medscape.com/viewarticle/764433 Miller R: Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
- Markusse IM, Dirven L, Han KH, et al. Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best? Arthritis Care Res (Hoboken). 2015;67:739–745.
- McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials. 2010;11:31.